# Phase 2 esophageal cancer trials recruiting: 87 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 87 trials in phase 2 for esophageal cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 esophageal cancer trials: 87 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/esophageal-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 87
- Recruiting or not yet: 87
- Read on: November 19, 2026

## Trials

The 25 newest of 87, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 7, 2026 | NCT07863141 | A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC... | Sun Yat-sen University | Phase 2 | Recruiting | Esophageal Cancer (EC) | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863141) |
| August 31, 2026 | NCT07795749 | Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B) | University of California, Irvine | Phase 2 | Recruiting | Esophageal Carcinoma, Gastric Cancer (Diagnosis), Colorectal Adenocarcinoma, Appendiceal Adenocarcinoma, Small Bowel... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07795749) |
| August 21, 2026 | NCT07780721 | Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer | The Affiliated Hospital of Putian University | Phase 2 | Not yet recruiting | Esophageal Cancer | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780721) |
| August 18, 2026 | NCT07770672 | An Exploratory Clinical Study of Accurate Efficacy Assessment of Neoadjuvant Immunotherapy in Locally Advanced Esophageal Squamous Cell... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Esophageal Cancer, ESCC | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770672) |
| August 18, 2026 | NCT07770100 | Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV) | Sponsor not shown (see the record) | Phase 2 | Recruiting | Head and Neck Cancer, Non-Small Cell Lung Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer (GC) | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770100) |
| July 29, 2026 | NCT07733830 | Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCC | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Recruiting | Esophageal Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733830) |
| July 9, 2026 | NCT07692204 | A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer | Sanofi | Phase 2 | Recruiting | Gastric Cancer, Oesophageal Carcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07692204) |
| July 6, 2026 | NCT07685938 | Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease | UNC Lineberger Comprehensive Cancer Center | Phase 2 | Recruiting | Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685938) |
| June 4, 2026 | NCT07625930 | RESTAGE (REpurposing STAtins to Improve Outcomes in GastroEsophageal Cancer) Trial | McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 2 | Not yet recruiting | Gastroesophageal Adenocarcinoma | 184 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625930) |
| June 1, 2026 | NCT07617246 | The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by... | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Recruiting | Esophagus Cancer, Lung Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617246) |
| May 22, 2026 | NCT07603375 | Upfront Chemotherapy With Radiation Therapy (CRT) Followed by Chemotherapy in Localized Esophageal Adenocarcinoma | Duke University | Phase 2 | Recruiting | Esophageal Adenocarcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07603375) |
| April 15, 2026 | NCT07530549 | A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Chemoimmunotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Not yet recruiting | Local Advanced Esophageal Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07530549) |
| April 15, 2026 | NCT07530094 | Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable... | Sponsor not shown (see the record) | Phase 2 | Recruiting | Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07530094) |
| April 9, 2026 | NCT07519486 | Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC | Sichuan University | Phase 2 | Recruiting | Esophageal Squamous Cell Carcinoma, Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07519486) |
| March 6, 2026 | NCT07455019 | A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Esophageal Cancer | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455019) |
| February 27, 2026 | NCT07435454 | Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell... | Jiangsu Cancer Institute & Hospital | Phase 2 | Recruiting | Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07435454) |
| January 29, 2026 | NCT07376876 | Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 | Not yet recruiting | Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Cancer | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07376876) |
| January 9, 2026 | NCT07330583 | Stereotactic Body Radiation Therapy (SBRT) and Immunotherapy for Oligometastatic Esophageal Cancer | AHS Cancer Control Alberta | Phase 2 | Not yet recruiting | Esophageal Cancer | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07330583) |
| January 7, 2026 | NCT07324018 | Spirulina Derivative for Radiation Esophagitis | West China Hospital | Phase 2 | Not yet recruiting | Radiation-induced Esophagitis | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07324018) |
| December 16, 2025 | NCT07283991 | QL1706 Plus Chemotherapy for Borderline Resectable Esophageal Cancer | Ruijin Hospital | Phase 2 | Not yet recruiting | Esophageal Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07283991) |
| November 18, 2025 | NCT07233850 | A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers | Shenyang Sunshine Pharmaceutical Co., LTD. | Phase 2 | Not yet recruiting | Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma... | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07233850) |
| October 31, 2025 | NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy | Sponsor not shown (see the record) | Phase 2 | Recruiting | Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC), Hepatocellular... | 880 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223424) |
| October 30, 2025 | NCT07222657 | Liquid Nitrogen Spray Cryotherapy Prior to Neoadjuvant Systemic Therapy in Esophageal Adenocarcinoma | Case Comprehensive Cancer Center | Phase 2 | Recruiting | Esophageal Adenocarcinoma, Esophageal Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07222657) |
| September 23, 2025 | NCT07188103 | Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinoma | Anhui Provincial Hospital | Phase 2 | Recruiting | Esophageal Squamous Cell Carcinoma | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07188103) |
| September 9, 2025 | NCT07162506 | dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Recruiting | Esophageal Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07162506) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 6 |
| Tianjin Medical University Cancer Institute and Hospital | 5 |
| Fujian Cancer Hospital | 4 |
| Shanghai Chest Hospital | 4 |
| OHSU Knight Cancer Institute | 2 |
| The First Affiliated Hospital of Zhengzhou University | 2 |
| Zhejiang Cancer Hospital | 2 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
| Peking University Cancer Hospital & Institute | 2 |
| Hebei Medical University Fourth Hospital | 2 |
| AHS Cancer Control Alberta | 2 |
| The First Affiliated Hospital with Nanjing Medical University | 2 |
| The First Affiliated Hospital of Xiamen University | 1 |
| University of California, Irvine | 1 |
| Australasian Gastro-Intestinal Trials Group | 1 |
| Case Comprehensive Cancer Center | 1 |
| Duke University | 1 |
| Anhui Provincial Hospital | 1 |
| National University Hospital, Singapore | 1 |
| Fudan University | 1 |
| Rutgers, The State University of New Jersey | 1 |
| Erasmus Medical Center | 1 |
| M.D. Anderson Cancer Center | 1 |
| Fujian Medical University Union Hospital | 1 |
| Centre Leon Berard | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 52 |
| United States | 18 |
| Netherlands | 4 |
| Spain | 4 |
| Canada | 4 |
| Australia | 3 |
| France | 3 |
| Germany | 3 |
| South Korea | 3 |
| Norway | 2 |
| Taiwan | 2 |
| United Kingdom | 2 |
| Italy | 2 |
| Japan | 2 |
| New Zealand | 1 |
| Singapore | 1 |
| Georgia | 1 |
| Belgium | 1 |
| Hungary | 1 |
| Denmark | 1 |
| Switzerland | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hospices in the United States](https://specstream.ai/data/businesses/hospices/united-states)
- [Pulmonology practices in the United States](https://specstream.ai/data/businesses/pulmonology-practices/united-states)
- [B2B environmental companies in the United States](https://specstream.ai/data/businesses/b2b-environmental-companies/united-states)
- [Financial advisory firms in the United States](https://specstream.ai/data/businesses/financial-advisory-firms/united-states)
- [Patent law firms in the United States](https://specstream.ai/data/businesses/patent-law-firms/united-states)
- [Wholesale grocers in the United States](https://specstream.ai/data/businesses/wholesale-grocers/united-states)
